SkinCeuticals Unveils A.G.E. Interrupter Ultra Serum: A Revolutionary Anti-Aging Solution for GLP-1 Weight Loss Drug Users
SkinCeuticals has unveiled its most anticipated product of 2025 – the A.G.E. Interrupter Ultra Serum ($185). This innovative product is specifically designed and tested for users of GLP-1 weight loss medications. The double-patented formula addresses skin laxity, a growing concern as rapid weight loss from drugs like Ozempic and Wegovy often leads to sagging skin and volume loss.
The breakthrough serum features a potent 34.6% concentration of Flavo-Proxylane™, Rhamnose, and Gentiana Lutea Root Extract. These ingredients are clinically proven to:
- Lift skin by up to 18%
- Reduce wrinkles by up to 16%
- Improve skin smoothness by up to 54% in just 12 weeks
The formula targets glycation and collagen degradation – key factors in aging skin that can be accelerated by rapid weight changes.
“We are laser-focused on medical trends driving consumers to clinics, and that’s how we got the idea to test this serum with GLP-1 patients,” said Tara Pyle, General Manager at SkinCeuticals.
With an estimated 30 million Americans expected to use weight loss drugs by 2030, this launch represents SkinCeuticals’ strategic entry into the expanding GLP-1 market. The serum launched on August 4, 2025, and is available at SkinCeuticals.com and partner dermatology practices nationwide.